03 October 2018 1 Min Read
$25m IPO envisioned for ‘magic mushrooms’ to treat depression
On the back of medical and financial interest in marijuana, psilocybin is heading to the labs too
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In